In people with no history of CV disease, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels can predict a higher risk of developing CV disease across various blood pressure and pulse pressure ...

Dallas, TX - The addition of natriuretic peptide testing to the traditional clinical evaluation of patients with dyspnea of suspected cardiac origin cut the duration of emergency-department visits by ...

NT-proBNP testing should become compulsory for referring patients to specialist heart failure services to improve diagnosis, ...

LONDON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited, a next-generation point of care diagnostics company, today announced it has commenced commercial shipment of its point of care NT-proBNP ...

The LumiraDx NT-proBNP and the LumiraDx D-Dimer tests are currently the only quantitative direct fingerstick assays produced for each test. Run on the highly portable LumiraDx Platform, they are ...

Measuring N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels preoperatively among patients scheduled to undergo inpatient noncardiac surgery can strongly predict the risk of major cardiac ...

Zomedica launches two canine assays for TRUFORMA, including NT-proBNP for heart disease and progesterone for breeding. The assays provide reference lab-level accuracy in-clinic, enhancing diagnostics ...

Q: Rambo, my 2-year-old cat, was breathing fast during his annual wellness exam. His veterinarian said his rapid breathing could be due to stress, heart disease or a respiratory condition such as ...

A large-scale analysis has shown that a blood test previously found useful in diagnosing or ruling out heart failure in emergency room patients remains effective in patients with chronic kidney ...

Run on the highly portable LumiraDx Platform, the LumiraDx NT-proBNP test is a quantitative, fingerstick blood assay designed for near-patient testing with lab-comparable results in 12 minutes. It is ...